Nexeon MedSystems Inc. (NXNN) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Nexeon MedSystems Inc. (NXNN) trades at $0.0001 with AI Score 61/100 (Grade B+). Nexeon MedSystems Inc. is a medical device company focused on developing and commercializing neurostimulation technology for neurological disorders. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for NXNN: NXNN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NXNN against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
NXNN: 2/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Nexeon MedSystems Inc. (NXNN) Healthcare & Pipeline Overview
Nexeon MedSystems Inc. develops neurostimulation technology for neurological disorders, focusing on deep brain stimulation (DBS) systems like Viant for Parkinson's disease, Essential Tremor, and Dystonia. Operating in the competitive medical device industry, Nexeon aims to address unmet needs in neurostimulation therapies, but faces challenges typical of early-stage medical device companies.
What Is the Investment Thesis for NXNN?
Nexeon MedSystems Inc. presents a high-risk, high-reward investment opportunity in the neurostimulation market. The company's focus on the Viant DBS system for Parkinson's disease and other neurological disorders addresses a significant unmet medical need. Key value drivers include successful completion of clinical trials, regulatory approvals in the US and Europe, and subsequent commercialization of the Viant system. However, the company's negative profit margin of -65.9% and gross margin of -9.6% indicate significant financial challenges. The high beta of 486.97 suggests extreme volatility. Growth catalysts include expansion into new neurostimulation markets and potential partnerships. Investors should carefully weigh the potential for significant returns against the substantial risks associated with an early-stage medical device company operating in a highly regulated and competitive industry.
Based on FMP financials and quantitative analysis
NXNN Key Highlights
Nexeon MedSystems Inc. specializes in neurostimulation technology for neurological disorders.
- The company is developing the Viant deep brain stimulation (DBS) system for Parkinson's disease, Essential Tremor, and Dystonia.
- Nexeon MedSystems Inc. has a negative profit margin of -65.9%, indicating significant financial challenges.
- The company's gross margin is -9.6%, reflecting high costs relative to revenue.
- The stock exhibits a high beta of 486.97, suggesting extreme volatility compared to the overall market.
Who Are NXNN's Competitors?
NXNN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CNVIF Conavi Medical Corp. | $0.13 | -1.19% | $11.4M | 66 |
| VPTDF VentriPoint Diagnostics Ltd. | $0.07 | -4.02% | $13.8M | 62 |
| LHDX Lucira Health, Inc. | $0.45 | +0.00% | $18.4M | 64 |
| PLSM PLSM | $3.01 | +4.88% | $19.6M | 60 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.27 | -1.08% | $24.6M | 73 |
| RDGL Vivos Inc. | $0.05 | -5.33% | $26.5M | 61 |
| NVYTF Novacyt S.A. | $0.48 | -0.00% | $34.8M | 61 |
| DNAY Codex DNA, Inc. | $1.30 | +8.33% | $38.3M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NXNN's Key Strengths?
Proprietary neurostimulation technology.
- Focus on a growing market for neurological disorder treatments.
- Potential for expansion into multiple neurostimulation markets.
- Experienced management team.
What Are NXNN's Weaknesses?
Negative profit and gross margins.
- Limited financial resources.
- Dependence on regulatory approvals.
- Small market share compared to larger competitors.
What Could Drive NXNN Stock Higher?
Completion of clinical trials for the Viant DBS system in the US and Europe.
- Regulatory approvals for the Viant DBS system in the US and Europe.
- Expansion into new neurostimulation markets beyond DBS.
- Strategic partnerships with larger medical device companies or research institutions.
- Advancements in neurostimulation technology.
What Are the Key Risks for NXNN?
Negative return on equity (-18.8%) — the business is not currently generating profit on shareholder capital.
- Failure to obtain regulatory approvals for the Viant DBS system.
- Intense competition from established medical device companies.
- Product liability risks associated with neurostimulation devices.
- Limited financial resources and negative profit margins.
- Dependence on key personnel and intellectual property.
What Are the Growth Opportunities for NXNN?
- Expansion into New Neurostimulation Markets: Nexeon's technology platform has the potential to address multiple neurostimulation markets beyond DBS, including peripheral nerve stimulation, spinal cord stimulation, and vagus nerve stimulation. Each of these markets represents a significant growth opportunity, with the global spinal cord stimulation market projected to reach $3.5 billion by 2027. Successfully adapting their technology to these new applications could significantly expand Nexeon's revenue base and market share. The timeline for this expansion depends on further research and development, clinical trials, and regulatory approvals.
- Strategic Partnerships and Collaborations: Nexeon could pursue strategic partnerships with larger medical device companies or research institutions to accelerate the development and commercialization of its neurostimulation technology. Collaborations could provide access to additional funding, expertise, and distribution channels. For example, partnering with a company specializing in neuromodulation could enhance Nexeon's product offerings and market reach. The timing of such partnerships is uncertain but could materialize within the next 2-3 years as Nexeon progresses through clinical trials and regulatory milestones.
- Geographic Expansion into Europe: Nexeon is currently developing the Viant system for use in Europe, targeting Parkinson's disease, Essential Tremor, and Dystonia. Obtaining regulatory approval in Europe would open up a significant market opportunity, as the European market for neurostimulation devices is substantial. Successful expansion into Europe could increase Nexeon's revenue by 20-30% within the first few years. The timeline for European expansion depends on the completion of clinical trials and the regulatory approval process, which could take 1-2 years.
- Advancements in Neurostimulation Technology: Continuous innovation in neurostimulation technology could drive future growth for Nexeon. This includes developing more precise and targeted stimulation techniques, improving the battery life and usability of devices, and integrating artificial intelligence to personalize therapy. These advancements could lead to improved patient outcomes and increased adoption of Nexeon's devices. The timeline for these advancements is ongoing, with incremental improvements expected over the next 3-5 years.
- Increased Awareness and Adoption of DBS Therapy: As awareness of the benefits of DBS therapy for neurological disorders increases among patients and physicians, the demand for Nexeon's Viant system could grow. This includes educating patients about the potential benefits of DBS and training physicians on how to implant and program the devices. Increased adoption of DBS therapy could drive significant revenue growth for Nexeon over the long term. The timeline for this growth is gradual, with increasing awareness and adoption expected over the next 5-10 years.
What Threats Does NXNN Face?
- Intense competition from established medical device companies.
- Regulatory hurdles and delays.
- Product liability risks.
- Economic downturn affecting healthcare spending.
What Are NXNN's Competitive Advantages?
- Proprietary neurostimulation technology platform.
- Intellectual property protection through patents.
- Regulatory approvals for its devices.
- Established relationships with neurosurgeons and hospitals.
What Does NXNN Do?
Founded in 2015 and based in Dallas, Texas, Nexeon MedSystems Inc. is a medical device company specializing in neurostimulation technology. The company develops, manufactures, and commercializes devices that use electrical stimulation of neural tissues to treat various neurological disorders. Their core technology platform is designed to serve multiple neurostimulator markets, including deep brain stimulation (DBS), peripheral electrical nerve stimulation, sacral nerve stimulation, spinal cord stimulation, and vagus nerve stimulation. Nexeon's lead product is the Viant deep brain stimulation system. Viant is being developed for the treatment of Parkinson's disease in the United States and for Parkinson's disease, Essential Tremor, and Dystonia in Europe. The company's focus on neurostimulation reflects a growing trend in medical technology towards less invasive and more targeted therapies for neurological conditions. As a relatively young company with 62 employees, Nexeon is in the early stages of commercializing its technology and establishing its market presence. The company's success depends on obtaining regulatory approvals, demonstrating clinical efficacy, and securing market adoption for its neurostimulation devices.
What Products and Services Does NXNN Offer?
- Develops neurostimulation technology for treating neurological disorders.
- Manufactures neurostimulation devices.
- Commercializes neurostimulation technology.
- Focuses on electrical stimulation of neural tissues.
- Develops deep brain stimulation (DBS) systems.
- Targets Parkinson's disease, Essential Tremor, and Dystonia with the Viant system.
How Does NXNN Make Money?
- Develops and manufactures neurostimulation devices.
- Seeks regulatory approvals for its devices in the US and Europe.
- Commercializes its devices through direct sales and distribution networks.
- Generates revenue from the sale of neurostimulation devices.
What Industry Does NXNN Operate In?
Nexeon MedSystems Inc. operates within the medical device industry, specifically in the neurostimulation market. This market is characterized by technological innovation, stringent regulatory requirements, and intense competition. Nexeon competes with larger, more established medical device companies like Medtronic and Boston Scientific, as well as smaller, specialized players. Success in this market requires strong intellectual property, clinical data, and effective commercialization strategies.
Who Are NXNN's Key Customers?
- Patients with neurological disorders such as Parkinson's disease, Essential Tremor, and Dystonia.
- Neurosurgeons who implant the neurostimulation devices.
- Hospitals and medical centers that offer neurostimulation therapy.
Company Profile
Nexeon MedSystems Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Dallas, US. The company is led by CEO William Rosellini. NXNN has traded publicly since 2017.
Nexeon MedSystems Inc. (NXNN) Valuation Context
Relative to its peer group, NXNN's quantitative score of 61/100 is roughly in line with the peer average of 65/100.
Key Financial Metrics
Return on equity for Nexeon MedSystems Inc. stands at -18.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -10.7%, showing how much profit it generates from its asset base. A current ratio of 1.16 indicates the company holds enough short-term assets to cover its near-term obligations.
Earnings Track Record
Nexeon MedSystems Inc. has beaten Wall Street's EPS estimate in 2 of its last 3 reported quarters — more hits than misses. Reported results have landed about 0.9% below estimates on average.
NXNN Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Proprietary neurostimulation technology.
- Focus on a growing market for neurological disorder treatments.
- Potential for expansion into multiple neurostimulation markets.
- Experienced management team.
Bear Case
- Negative profit and gross margins.
- Limited financial resources.
- Dependence on regulatory approvals.
- Small market share compared to larger competitors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
NXNN Latest News
No recent news available for NXNN.
NXNN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NXNN.
Price Targets
Wall Street price target analysis for NXNN.
NXNN MoonshotScore
What does this score mean?
The MoonshotScore rates NXNN 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: William Rosellini
CEO
William Rosellini serves as the CEO of Nexeon MedSystems Inc. He has a background in biomedical engineering and law, holding degrees from Arizona State University. Rosellini has experience in the medical device industry, having previously founded and led other companies in the neurostimulation and medical technology space. His expertise includes product development, regulatory affairs, and commercialization strategies for medical devices.
Track Record: Under Rosellini's leadership, Nexeon MedSystems Inc. has focused on developing the Viant DBS system and advancing it through clinical trials and regulatory pathways. He has overseen the company's efforts to secure intellectual property protection and establish partnerships with key stakeholders. His strategic decisions have shaped the company's focus on addressing unmet needs in the neurostimulation market.
NXNN OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Nexeon MedSystems Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial information available and may be subject to greater risks compared to companies listed on major exchanges like NYSE or NASDAQ. Investing in OTC Other stocks involves higher scrutiny and due diligence due to the potential for limited transparency and regulatory oversight.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Higher potential for fraud and manipulation.
- Lower liquidity and trading volume.
- Greater price volatility.
- Limited regulatory oversight and investor protection.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Review the company's regulatory compliance and legal history.
- Check for any red flags or warning signs.
- Consult with a qualified financial advisor.
- Development of a tangible product (Viant DBS system).
- Focus on a specific market need (neurological disorder treatments).
- Experienced CEO with a background in medical devices.
- Efforts to secure intellectual property protection.
- Ongoing clinical trials and regulatory submissions.
NXNN Healthcare Stock FAQ
What does the AI Score mean for NXNN?
NXNN holds an AI Score of 61/100 (Grade: B+). This is an educational research signal, not a buy or sell recommendation. Nexeon MedSystems Inc. is a medical device company focused on developing and commercializing neurostimulation technology for neurological disorders. Their primary focus is on deep brain stimulation …
What does Nexeon MedSystems Inc. do?
Nexeon MedSystems Inc. is a medical device company that develops, manufactures, and commercializes neurostimulation technology for treating neurological disorders. Their primary focus is on deep brain stimulation (DBS) systems, with their lead product being the Viant system designed for patients with Parkinson's disease, Essential Tremor, and Dystonia. The company aims to improve the quality of life for patients suffering from these conditions through innovative neurostimulation therapies.
What do analysts say about NXNN stock?
As of 2026-03-17, there is no available analyst coverage for NXNN stock. Given its OTC listing and early stage, major brokerage firms may not actively cover the company. Investors should rely on their own due diligence and research to assess the company's prospects. Key valuation metrics to consider include the company's market capitalization, revenue growth potential, and cash burn rate.
What are the main risks for NXNN?
Nexeon MedSystems Inc. faces several significant risks typical of early-stage medical device companies. These include the risk of failing to obtain regulatory approvals for its Viant DBS system, intense competition from larger and more established medical device companies, potential product liability claims, limited financial resources and negative profit margins, and dependence on key personnel and intellectual property.
What revenue streams does Nexeon MedSystems Inc. have in healthcare?
Currently, Nexeon MedSystems Inc. does not have established revenue streams as it is still in the development and clinical trial phase for its Viant DBS system. Potential future revenue streams would primarily come from the sale of the Viant system and related accessories to hospitals and medical centers.
How does Nexeon MedSystems Inc. navigate regulatory approval processes?
Nexeon MedSystems Inc. is currently navigating the regulatory approval processes for its Viant DBS system in both the United States and Europe. This involves conducting clinical trials to demonstrate the safety and efficacy of the device, submitting detailed regulatory filings to the FDA in the US and the EMA in Europe, and responding to any questions or requests from the regulatory agencies.
What are the key factors to evaluate for NXNN?
Nexeon MedSystems Inc. (NXNN) holds an AI score of 61/100 (moderate). presents a high-risk, high-reward investment opportunity in the neurostimulation market. Not financial advice.
How frequently does NXNN data refresh on this page?
NXNN's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven NXNN's recent stock price performance?
Nexeon MedSystems Inc. (NXNN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary neurostimulation technology. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited due to the company's OTC status and early stage of development.
- Analyst coverage is unavailable, requiring independent investor due diligence.